¿Qué tenemos que tener en cuenta para el aumento de la supervivencia en 2ª línea de cáncer de pulmón?

31 / 54

Felip E et al, ESMO 2017; 1301 PD
OS (3 years’ minimum follow-up)
• Median duration of therapy for patients treated with nivolumab and docetaxel, respectively, was 2.8 (range, 0–
51.8+) months and 2.1 (range, 0–20.0) months
• After >3 years’ minimum follow-up in CheckMate 017 and 057, 5% and 7% of nivolumab-treated patients
remained on study treatment, respectively; no docetaxel-treated patients remained on study treatment
CheckMate 057 CheckMate 017